VERONA PHARMA
VRNADrugs in Pipeline
14
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
This month
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
Ensifentrine 3 mg Phase 2 Est. Readout
Primary completion for Ensifentrine 3 mg trial (NCT07016412) in Chronic Obstructive Pulmonary Disease
Source2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
Ensifentrine 3 mg twice daily
COPD
Ensifentrine
Chronic Obstructive Pulmonary Disease
Nebulized Ensifentrine Suspension; 3 mg
Non-cystic Fibrosis Bronchiectasis
Part A: RPL554
Pulmonary Disease, Chronic Obstructive
Glycopyrrolate (85 μg)
Chronic Obstructive Pulmonary Disease
Tiotropium/olodaterol (Respimat)
COPD
Ensifentrine 3 mg
Chronic Obstructive Pulmonary Disease
RPL554
Cystic Fibrosis
Salbutamol
Chronic Obstructive Pulmonary Disease
Glycopyrrolate 21.25 mcg
Chronic Obstructive Pulmonary Disease
1.5 mg RPL554 plus tiotropium
Chronic Obstructive Pulmonary Disease Moderate
Ensifentrine Dose 1
Coronavirus Infection
Part B: RPL554
COPD
RPL554 suspension
COPD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ensifentrine 3 mg twice daily | Phase 3 | COPD | - | - |
Ensifentrine | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Nebulized Ensifentrine Suspension; 3 mg | Phase 2 | Non-cystic Fibrosis Bronchiectasis | - | - |
Part A: RPL554 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Glycopyrrolate (85 μg) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Tiotropium/olodaterol (Respimat) | Phase 2 | COPD | - | - |
Ensifentrine 3 mg | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
RPL554 | Phase 2 | Cystic Fibrosis | - | - |
Salbutamol | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Glycopyrrolate 21.25 mcg | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
1.5 mg RPL554 plus tiotropium | Phase 2 | Chronic Obstructive Pulmonary Disease Moderate | - | - |
Ensifentrine Dose 1 | Phase 2 | Coronavirus Infection | - | - |
Part B: RPL554 | Phase 2 | COPD | - | - |
RPL554 suspension | Phase 2 | COPD | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in VERONA PHARMA's drug pipeline?→
CatalystAlert tracks 14 drug candidates in VERONA PHARMA's (VRNA) pipeline across Phase 3, Phase 2. Its lead program is Ensifentrine 3 mg twice daily (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is VERONA PHARMA's next FDA catalyst?→
VERONA PHARMA's (VRNA) next tracked catalyst is a Phase 2 expected August 17, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VRNA biotech catalysts?→
Add VRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow VERONA PHARMA's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.